RAS proteins are important direct activators of p110a, p110g, and p110d type I phosphoinositide 3-kinases (PI3Ks), interacting via an amino-terminal RAS-binding domain (RBD). Here, we investigate the regulation of the ubiquitous p110b isoform of PI3K, implicated in G-protein-coupled receptor (GPCR) signaling, PTEN-loss-driven cancers, and thrombocyte function. Unexpectedly, RAS is unable to interact with p110b, but instead RAC1 and CDC42 from the RHO subfamily of small GTPases bind and activate p110b via its RBD. In fibroblasts, GPCRs couple to PI3K through Dock180/Elmo1mediated RAC activation and subsequent interaction with p110b. Cells from mice carrying mutations in the p110b RBD show reduced PI3K activity and defective chemotaxis, and these mice are resistant to experimental lung fibrosis. These findings revise our understanding of the regulation of type I PI3K by showing that both RAS and RHO family GTPases directly regulate distinct ubiquitous PI3K isoforms and that RAC activates p110b downstream of GPCRs.
INTRODUCTION
The type I phosphoinositide 3-kinases (PI3Ks) are critical signaling proteins involved in the regulation of cell growth, survival, motility, and metabolism. In mammals, there exist four isoforms of the type I PI3K catalytic p110 subunits: a, b, g, and d. Of these, a and b are ubiquitously expressed, whereas g and d have more limited distribution, most notably in hematopoietic cells . The lipid kinase activity of p110a is regulated downstream of receptor tyrosine kinases by the binding of tyrosine-phosphorylated proteins to its regulatory p85 subunit, resulting in attenuation of its autoinhibitory activity. In addition, activated RAS proteins bind directly to an N-terminal RAS-binding domain (RBD) on p110a, acting synergistically with the input from tyrosine-phosphorylated proteins to optimally activate lipid kinase activity (Rodriguez-Viciana et al., 1994 , 1996 . Proof of the pathophysiological importance of the direct interaction of RAS with p110a came from the generation of mice bearing germline mutations in the RBD of p110a, which were found to be highly resistant to mutant-RAS-induced lung and skin cancer formation (Gupta et al., 2007) .
The direct binding of RAS to p110g has also been studied in detail. The 3D structure of RAS bound to p110g has been determined, and RAS has been shown to activate the lipid kinase activity of p110g cooperatively with input from Gbg subunits via the regulatory p101 subunit (Pacold et al., 2000) . Mice with mutations in the RBD of p110g show neutrophil defects in the regulation of PI3K activity by some G-protein-coupled receptors (GPCRs) (Suire et al., 2006) . RAS also has been reported to bind and activate p110d in vitro (Vanhaesebroeck et al., 1997) . In addition, RBD mutations have been used to demonstrate that input of RAS binding to the single Drosophila type I PI3K is critical in insulin-pathway-controlled developmental growth (Orme et al., 2006) and that RAS binding is required for PI3K activation by chemoattractants in Dictyostelium (Funamoto et al., 2002) . p110b has been much less thoroughly studied than p110a. It appears to be relatively insensitive to activation by growth factor receptor tyrosine kinase signaling but important downstream of certain GPCRs, including those for lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), making p110b the only GPCR-regulated type I PI3K isoform outside the hematopoietic system (Ciraolo et al., 2008; Guillermet-Guibert et al., 2008; Jia et al., 2008) . p110b may also play an important role in cancer because mouse models of breast and prostate cancer, as well as a number of human cancer cell lines, depend on p110b, particularly in the setting of PTEN loss (Ciraolo et al., 2008; Jia et al., 2008) . In platelets, p110b is essential for integrin-dependent adhesion and clot formation (Jackson et al., 2005; Martin et al., 2010) , leading to the intense effort to develop isoformspecific p110b inhibitors, some of which are now in clinical trials as antiplatelet and anticancer agents (NCT01458067, NCT00688714).
The molecular basis of how p110b can exert these distinct functions is poorly understood. p110b is overall structurally similar to other p110 catalytic subunits and engages the very same p85 type regulatory subunits as p110a, albeit in a somewhat different way (Zhang et al., 2011) . Early reports have found p110b to associate with Gbg subunits from heterotrimeric G proteins, which can directly stimulate its lipid kinase activity in vitro (Kurosu et al., 1997; Maier et al., 1999) . It has, however, remained entirely unclear whether the p110b RBD contributes to p110b activation and function, and despite the apparently similar level of relatedness between the RBDs across the four isoforms, a systematic analysis of RAS effector proteins failed to detect any activation of p110b by RAS in cotransfected cells (Rodriguez-Viciana et al., 2004) .
In this report, we explore the role of p110b regulation through its RBD for PI3K signaling and function. We present extensive in vitro work to show that p110b is the only type I PI3K isoform not regulated by RAS and to identify the RHO family GTPases RAC and CDC42 as direct isoform-specific RBD interactors and activators of p110b. We go on to show that GPCRs couple to PI3K via Dock180/Elmo1-mediated RAC activation and subsequent interaction with p110b. Mouse embryonic fibroblasts (MEFs) from p110b RBD mutant mice show reduced PI3K activity and mice are resistant to bleomycin-induced lung fibrosis, a pathology that has been linked with LPA signaling. These findings explain longstanding inconsistencies and revise our understanding of type I PI3K regulation by small GTP-binding proteins, providing molecular insight into the regulation and function of the ubiquitous p110b isoform.
RESULTS

PI3K p110b Is Not a RAS Target Protein
To investigate the role of RAS in regulating p110b, we set out to characterize the biochemical interaction between the two in vitro. In glutathione S-transferase (GST) pull-down studies using recombinant, GTPgS-loaded HRAS, KRAS, and NRAS as baits, we found strong and specific interaction between all three RAS proteins and p110a ( Figure 1A) . In contrast, p110b bound to none of the RAS proteins, but did bind to RAB5, a previously identified GTPase interactor of p110b (Christoforidis et al., 1999) . Mutating key residues within the RBD of p110a (T208D/ K227A) abrogated RAS binding, whereas introduction of analogous mutations (see below for details) into p110b did not affect RAB5 binding. Similar results were obtained when we used recombinant full-length GST-p110/p85 complexes to pull down active RAS or RAB5 proteins ( Figure 1B) . Moreover, when we expressed constitutively active RAS or RAB5, along with p110a/ p85 or p110b/p85 in COS7 cells, and measured PIP 3 -levels (Figure 1C) or steady-state phospho-AKT ( Figure S1A available online) as indicators of PI3K activity, HRAS and KRAS strongly enhanced p110a activity, whereas p110b was not stimulated by either RAS proteins or RAB5.
An Intact RBD Is Essential for p110b Activity in Cells
The modest RBD sequence similarity among the four paralogs of type I PI3K is shown in Figure 1D . Even though the overall structural organization of the p110b RBD is conserved (Zhang et al., 2011) , we speculated that because we cannot detect any interaction with RAS, it might have lost or altered its function. We therefore mutated two highly conserved key residues within the p110b RBD to generate a p110b-S205D/K224A double mutant (p110b-RBD-DM; Figure 1E ). Analogous mutations in p110a and p110g disrupt RAS binding (Gupta et al., 2007; Pacold et al., 2000) . In vitro, the basal lipid kinase activity of purified recombinant p110b-RBD-DM protein was indistinguishable from its wild-type counterpart prepared in parallel ( Figure 1F ). Moreover, p110b-RBD-DM was still stimulated by the addition of purified recombinant Gbg subunits, alone or in combination with a platelet-derived growth factor receptor (PDGFR)-derived phosphotyrosine peptide (pY740), indicating that the RBD mutations had no intrinsic effect on p110b lipid kinase activity or RBD-independent stimulatory input ( Figure 1G ). However, RBD mutant p110b was much less active than wild-type when expressed in COS7 cells (Figures 1H and S1B) even when Gbg subunits were coexpressed or a myristoylation signal was added, pointing to a critical role of the RBD for p110b activity in living cells.
p110b Interacts with Distinct RAS Subfamily GTPases
To identify RBD interactors of p110b, we probed all 34 murine members of the RAS subfamily of small GTPases (RFGs) for binding to p110b/p85 ( Figure S1C ). Parallel experiments were performed with p110a/p85, p110g/p101, and p110d/p85, respectively ( Figure S1D ). Strikingly, whereas all non-b isoforms interacted with the three prototypical RAS proteins and a partially overlapping subset of closely related RFGs (RRAS1, RRAS2, MRAS, and ERAS), p110b bound to none of those (Figure 2A) . Instead, p110b exclusively bound to the more distantly related DIRAS1 and DIRAS2 proteins in a GTP-dependent manner ( Figure S1C ). DIRAS selectively bound wild-type and not RBD mutant p110b ( Figure S2B ), suggesting binding to the RBD. However, DIRAS failed to stimulate p110b lipid kinase activity in vitro ( Figure 2C ) and in cells, where constitutively active DIRAS proteins seemed to repress rather than elevate phospho-AKT when coexpressed along with p110b ( Figure 2B ), making DIRAS an unlikely in vivo activator of p110b.
p110b Is a Direct RAC/CDC42 Target Protein When comparing DIRAS with RAS, an obvious difference is the substitution of Asp33 within the G2 box of RAS with Ile37 in DIRAS ( Figure 2D ). This substitution is relevant to PI3K binding because an HRAS-D33I mutant showed attenuated binding to p110a and DIRAS1-I37D showed reduced binding to p110b, even though exchange of this residue did not enable RAS binding to p110b or DIRAS binding to p110a ( Figure S2A ), pointing to additional, G2-box-independent determinants of PI3K isoform specificity. Several members of the RHO subfamily of small GTPases harbor a hydrophobic isoleucine or valine residue in this position ( Figure S2C ), which prompted us to test p110b for binding to representative RHO family GTPases ( Figure S2D) . Surprisingly, p110b bound to both RAC1 and CDC42 in a GTPdependent manner. Weaker binding to RHOG and minimal binding to RHOA was also observed ( Figure 2E ). Importantly, RAC1, CDC42, RHOG, and RHOA preparations bound similar amounts of GTP, indicating proper folding and functionality (Figure 2E, right lower graph) , and a RAC1-I33D mutant showed reduced binding to p110b ( Figure S2E ), confirming a key role of this residue in GTPase binding to p110b. The RAC1/CDC42-p110b interaction was isoform specific because neither RAC1 nor CDC42 significantly bound non-b isoforms under parallel conditions ( Figures 2F and S2F ). Strikingly, GTPgS-loaded RAC1 or CDC42 strongly stimulated p110b lipid kinase activity in vitro ( Figure 2G ), alone and in cooperation with a phosphotyrosine peptide (pY740), or when p110b was complexed with a less inhibitory, truncated p85 (Dp85 schematic in Figure 3C ). Stimulation of p110b by active RAC1 and CDC42 was dose dependent ( Figure 2H ). Coexpression of constitutively active RAC1 or CDC42 ( Figure S2G , lanes 4-6), but not RHOA ( Figure S2H ), along with p110b/p85 in COS7 cells strongly elevated cellular phospho-AKT and PIP 3 levels ( Figure 2I ), indicating that both GTPases activate p110b in transfected cells. PIP 3 levels were further enhanced by coexpression of Gb 1 /Gg 2 subunits or by myristoylation of p110b ( Figure 2I ). In contrast, GTPgS-loaded RAC1/CDC42 did not stimulate p110a in vitro ( Figure S2I ), nor did V12-RAC1/CDC42 cooperate with p110a, p110g, or p110d to elevate cellular phospho-AKT levels (Figure S2J) . Taken together, these data show that the RHO family GTPases RAC1 and CDC42 bind to p110b in an isoform-specific manner and potently and directly stimulate its lipid kinase activity.
RAC and CDC42 Are RBD Interactors of p110b
We next aimed to confirm that RAC and CDC42 are RBD interactors of p110b. Purified recombinant wild-type p110b/p85 bound to RAC1 and CDC42 in a concentration-dependent manner, whereas p110b-RBD-DM/p85 complexes showed no binding ( Figure 3A) . Similarly, RBD mutant p110b was not stimulated by active RAC1 or CDC42 in vitro ( Figure 3B ) or in cells (Figure S2E, . To test whether the BCR homology domain (BHD) on p85, which had previously been shown to bind RAC and CDC42 (Bokoch et al., 1996; Zheng et al., 1994) , is required for RAC/CDC42 binding to p110b, we truncated p85 (Dp85 schematic in Figure 3C ) and probed for binding of p110b/Dp85 to RAC1 and CDC42 in vitro. Intriguingly, binding was unaffected by removal of the BHD but completely disrupted when full-length p85 was in complex with RBD mutant p110b, strongly arguing for the RBD as the RAC/CDC42-binding site. To further corroborate these findings, we generated 43 single point mutations covering 37 residues across the p110b RBD and assayed these mutants for binding to RAC1 and CDC42 ( Figures 3D, S3A , and S3B). Of those, 17 mutations of 14 RBD residues affected binding to both GTPases without affecting p110b protein stability. Several of these residues were part of the RBDb1 and b2 sheets or the loop adjacent to the RBDa1 helix (Zhang et al., 2011) , areas known to be important for RAS binding in non-b isoforms (Pacold et al., 2000) . Finally, we employed isothermal titration calorimetry (ITC) to study thermodynamics of the RAC1/CDC42-p110b interaction. In solution, RAC1,GTPgS bound to p110b/Dp85 with a molar ratio close to 1 and an average K d of 1.42 mM, whereas the affinity measured for CDC42,GTPgS was 3.1 mM ( Figures  3E and 3F ). Similar affinities have been reported for the RAS-p110a and RAS-p110g interactions (Pacold et al., 2000; Rodriguez-Viciana et al., 1996) , indicating that RAC1 and CDC42 are plausible RBD interactors of p110b. No binding was observed between GTPgS-loaded RAC1/CDC42 and p110a or p110b-RBD-DM, respectively ( Figure S3C ).
p110b-RBD-DM Mice Show Signs of Reduced PI3K Activity
To study the role of interactor binding to the p110b RBD for PI3K signaling in vivo, we generated mice harboring the two p110b RBD point mutations (S205D/K224A) within their germline. Homologous recombination in embryonic stem (ES) cells was employed to replace exon 6 of the murine Pik3cb gene (Figure S4A ), and germline transmission was achieved by eightcell embryo injection ( Figures S4B and S4C ). p110b-RBD-DM mice were viable and fertile, although numbers of homozygous animals at the time of biopsy (around day 14) were moderately reduced (73 where 105 were expected; p < 0.02; Figure 4A ), indicating incomplete lethality for undetermined reasons. Newborn homozygous p110b-RBD-DM pups were smaller than their wild-type littermates ( Figure 4B ). The size difference in adult mice was subtle but remained significant when same-sex Figure 1 . PI 3-Kinase p110b Is Unable to Interact with RAS (A) p110b does not bind to GTP-loaded RAS proteins. Purified recombinant, GTPgS-loaded HRAS, KRAS, NRAS, and RAB5 were incubated with lysates from COS7 cells expressing FLAG-p110a/p85 or FLAG-p110b/p85, wild-type (WT), or RBD double mutant (DM). (B) Active RAS proteins do not bind to immobilized p110b/p85. Purified recombinant GST-p110a/p85 and GST-p110b/p85 were incubated with lysates from COS7 cells expressing Myc-tagged, constitutively active HRAS, KRAS, NRAS, and RAB5. (C) Active RAS proteins do not stimulate p110b in cells. Lipids were extracted and PIP 3 levels measured from COS7 cells expressing constitutively active mutants of HRAS, KRAS, NRAS, and RAB5, alone or in combination with p110a/p85 or p110b/p85 (n = 3; mean with SD; one-way ANOVA). (D) Type I PI3K RBDs show moderate sequence similarity. Alignment of amino acid sequences of all four type I PI3K RBDs (PIK3CB = p110b, PIK3CD = p110d, PIK3CA = p110a, PIK3CG = p110g). Orange represents RAS-binding residues in p110g, and arrows represent conserved ''RAS-binding'' residues. (E) Mutation of RBD key residues in p110b. The two point mutations are shown together with hypothetical interactor residues modeled on the RAS-p110g interaction. (F) Unaltered lipid kinase activity of recombinant p110b-RBD-DM protein. Lipid kinase assay assessing basal activities of purified recombinant p110b/p85 complexes (n = 3; mean with SEM). (G) p110b-RBD-DM protein remains sensitive to Gbg and phosphotyrosine. A representative lipid kinase assay assessing effect of recombinant Gbg and a PDGFR-derived phosphotyrosine peptide (pY740) on the activity of purified recombinant p85/p110b-WT and p85/p110b-RBD-DM is shown. (H) Activity of p110b-RBD-DM in living cells is reduced. Lipids were extracted and PIP 3 levels measured from COS7 cells expressing wild-type or RBD mutant p110b/p85. Gbg, coexpression of Gb 2 and Gg 1 ; Myr, myristoylated p110b (n = 3; mean with SEM; paired t test). See also Figure S1 . litter-and cage-mates were compared ( Figure 4C ). MEFs homozygous for the p110b RBD mutation proliferated at a significantly slower rate than their wild-type counterparts ( Figure 4D ), which was reflected by a higher percentage of cells in G1 (1% fetal calf serum [FCS]: 56.7% ± 0.32% versus 64.2% ± 0.53%, n = 4, p < 0.001; 10% FCS: 47.5% ± 3.0% versus 52.2% ± 3.9%, n = 4, p < 0.05), fewer cells in G2 (1% FCS: 24.5% ± 1.4% versus 21.0% ± 1.9%, n = 4, p < 0.05; 10% FCS: 23.9% ± 1.4% versus 21.1% ± 1.6%, n = 4, p < 0.05) and fewer cells in S phase for 1% FCS (1% FCS: 13.3% ± 1.0% versus 11.0% ± 169%, n = 4, p < 0.05) ( Figure 4E ). Moreover, p110b-RBD-DM MEFs showed lower steady-state phospho-AKT levels ( Figure 4F ), suggesting that stimulatory signaling to p110b via its RBD contributes to PI3K activity in vivo. Expression levels of p110b, p110a, and Lipids were extracted and PIP 3 levels measured from COS7 cells expressing constitutively active RAC1 or CDC42, alone or in combination with FLAG-p110b/p85. Gbg, coexpression of Gb 2 and Gg 1 ; Myr, myristoylated p110b (n = 2; mean with SD). Western blots show expression levels of FLAG-p110b and Myc-tagged GTPases. See also Figure S2 . p85 were indistinguishable among the genotypes ( Figure S4D ), and the stoichiometry of p110 subunit binding to p85 was undisturbed ( Figure S4E ).
RAC and CDC42 Regulate p110b In Vivo
To determine whether RAC and CDC42 are upstream activators of p110b in vivo, we transfected wild-type and p110b-RBD-DM MEFs with small interfering RNA (siRNA) pools (Dharmacon Ontarget plus) targeting these GTPases ( Figure 4G ). Although single knockdowns had only minor effects, combined knockdown of were added to purified recombinant p85/ p110b-WT or p85/p110b-RBD-DM in lipid kinase assays (n = 2; mean with SD). Data are part of experiment shown in Figure 2G . Figure S3 .
RAC1 and CDC42 significantly lowered phospho-AKT levels in wild-type, but not in p110b-RBD-DM cells, closing the gap in steady-state phospho-AKT levels between the genotypes and suggesting that endogenous RAC1 and CDC42 cooperatively activate p110b via its RBD. We next acutely expressed constitutively active mutants of RAC1 and CDC42 in wild-type, p110a-, and p110b-knockout MEFs (Figures 4H and S4F) . Both RAC1 and CDC42 increased steady-state phospho-AKT levels in wild-type and p110a-deleted cells but not in p110b-knockout MEFs. Moreover, expression of V12-RAC1 and V12-CDC42 failed to elevate phospho-AKT levels in p110b-RBD-DM MEFs, whereas V12-HRAS did so in both wild-type and p110b-RBD-DM MEFs ( Figure 4I ). Taken together, these findings indicate that RAC1 and CDC42 activate PI3K in living cells by isoformspecific regulation of p110b through its RBD.
Activation of p110b Downstream of GPCRs Requires an Intact RBD
To study whether the p110b RBD is required for coupling p110b to GPCRs, we stimulated wild-type and p110b-RBD-DM MEFs with the lipid growth factors and GPCR agonists LPA and S1P. Newborn pups from HET 3 HET crosses were collected on the morning of birth, weighed, and genotyped (n = 31; mean ±SEM; p = 0.011, t test). (C) Adult p110b-RBD-DM mice are smaller than their wild-type littermates. Weights of adult homozygous p110b-RBD-DM mice (12-30 weeks old) were compared to same-cage wild-type littermates (n = 39; mean ±SEM; paired t test). (D) Reduced proliferation of p110b-RBD-DM MEFs. Early passage primary MEFs were grown in culture following a modified 3T3 protocol (n = 2 per genotype). Population doubling rate was calculated as PDR = logðnðday 3Þ=nðseededÞÞ=log 2 (mean ±SEM; p < 0.001, two-way ANOVA). (E) Accumulation of p110b-RBD-DM cells in G1. Cell-cycle profiles of early passage wild-type and homozygous p110b-RBD-DM primary MEFs growing in 1% or 10% FCS (n = 4, means; SEM in the Results section). (F) p110b-RBD-DM MEFs show reduced steadystate phospho-AKT levels. Wild-type and p110b-RBD-DM MEFs were maintained in cell culture medium supplemented with 0%, 1%, or 10% FCS and harvested for western blot analysis. (G) RAC1 and CDC42 cooperatively sustain phospho-AKT levels in wild-type MEFs. Wild-type and p110b-RBD-DM MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting RAC1, CDC42, or both and harvested for western blot analysis 30 hr after transfection. Graph shows phospho-AKT normalized to total AKT (n = 3; mean with SEM, one-way ANOVA). (H) RAC1 and CDC42 activate p110b in vivo. Myc-V12-RAC1 and Myc-V12-CDC42 were nucleofected into immortalized wild-type, p110a-knockout, and p110b-knockout MEFs, along with a kinase-dead AKT reporter construct. The next day, cells were serum starved and harvested for western blot. (I) RAC and CDC42 fail to activate PI3K in p110b-RBD-DM cells. Myc-V12-RAC1, Myc-V12-CDC42, or Myc-V12-HRAS were nucleofected into wild-type and p110b-RBD-DM MEFs as described in (H). See also Figure S4 .
LPA and S1P dose-dependently induced both AKT and ERK phosphorylation in wild-type cells (Figures 5A and S5A) . These responses were sensitive to pertussis toxin ( Figure S5B ), confirming GPCR involvement. In p110b-RBD-DM MEFs, LPA-and S1Pinduced phosphorylation of AKT was strongly diminished, whereas ERK phosphorylation was undisturbed ( Figures 5A  and S5A) . Also, in time course experiments, AKT phosphorylation was more transient when the p110b RBD was mutated ( Figure 5B and not shown) . In contrast, p110b-RBD-DM MEFs responded normally to epidermal growth factor (EGF), plateletderived growth factor (PDGF), and insulin in dose-response (Figure S5C ) and time course experiments (data not shown). Notably, in p110b-knockout cells, AKT phosphorylation in response to LPA was completely abolished ( Figure 5C ), indicating that the RBD is essential for much but not all p110b activation downstream of GPCRs.
Activation of p110b Downstream of GPCRs Requires RAC
To test whether the identified p110b RBD interactors are required for linking p110b to GPCRs, we knocked down RAC1 and CDC42 in wild-type MEFs. Knockdown of RAC1 strongly impacted LPA/S1P-induced AKT phosphorylation, knockdown of CDC42 had only minor effects, and combination knockdown (C) LPA-induced AKT phosphorylation is entirely dependent on p110b. Immortalized wildtype, p110a-knockout, p110b-knockout, and p110b-RBD-DM MEFs were serum starved and stimulated with indicated doses of LPA for 5 min.
(D) LPA-/S1P-induced AKT phosphorylation requires RAC. Immortalized wild-type MEFs were transfected with scrambled duplex or gene-specific siRNA pools targeting RAC1, CDC42 or both. Serum-starved cells were stimulated with LPA (10 mM) or S1P (1 mM) for 5 min.
(E) LPA-/S1P-induced AKT phosphorylation requires RAC activity. Immortalized wild-type MEFs were serum starved, preincubated with EHT1864 for 30 min, and stimulated with LPA (10 mM) or S1P (1 mM) for 5 min.
(F) LPA induces rapid and transient activation of RAC. Serum-starved wild-type and p110b-RBD-DM MEFs were stimulated with LPA (10 mM) for indicated periods of time. RAC,GTP and total RAC were measured as described in the Extended Experimental Procedures (n = 3; mean with SEM). See also Figure S5. of both RAC1 and CDC42 had little additional effect compared to RAC1 knockdown alone ( Figure 5D ). Deconvolution experiments using single siRNA oligonucleotides confirmed the leading role of RAC1 in this pathway ( Figure S5D ). Neither RAC1 nor CDC42 knockdown affected LPA/S1P-induced phosphorylation of ERK or activation of either pathway induced by tyrosine kinase receptor agonists (EGF, PDGF, and insulin; Figure S5E ). Similarly, EHT1864, a direct inhibitor of RAC but not CDC42 activation, dose-dependently inhibited AKT phosphorylation induced by LPA/S1P ( Figure 5E ), but not EGF, PDGF, or insulin ( Figure S5F ). Therefore, acute loss or inhibition of RAC phenocopied the signaling defect observed in p110b-RBD-DM MEFs. In line with this, RAC was activated very rapidly upon LPA stimulation, reaching its peak activity within 20 s ( Figure 5F ).
Dock180/Elmo1 Activates RAC Downstream of GPCRs and Upstream of p110b
To provide further mechanistic insight into the GPCR-RAC-p110b pathway, we performed a small candidate siRNA screen to identify the guanine nucleotide exchange factor (RAC-GEF) involved. Transfection of wild-type MEFs with siRNA pools targeting the Dbl family RAC-GEFs Vav1-3, PREX1/2, and a-/ b-PIX had no clear effect on LPA/S1P-induced AKT phosphorylation ( Figures 6A and S6A) . In contrast, knockdown of the Dock family RAC-GEF Dock180 or its adaptor protein Elmo1 interfered with AKT phosphorylation induced by LPA and S1P ( Figure 6B and S6B), but not by EGF, PDGF, and insulin ( Figure S6C ). Specificity of results was confirmed in deconvolution experiments using individual siRNA oligonucleotides targeting Dock180 and Elmo1 (Figures S6D and S6E ). Knockdown of Elmo2 had no effect ( Figure S6F) . Moreover, knockdown of Dock180 abolished LPA-but not EGF-induced RAC activation ( Figure 6C Figure 6D) . Recently, Dictyostelium ElmoE has been reported to be a direct Gbg effector (Yan et al., 2012) . We thus probed Gbg subunits for direct binding to purified recombinant Elmo1 ( Figure 6E ) and found Gbg to strongly bind to full-length Elmo and several N-terminal fragments. This altogether suggests a model in which Dock180 is recruited downstream of GPCRs, possibly through binding of Gbg to the N terminus of Elmo1. At the same time, p110b is directly recruited by Gbg. RAC is activated in proximity to p110b and binds to the RBD to fully activate p110b lipid kinase activity (schematic in Figure 6F ). We could not detect any tyrosine phosphorylation on p85 in response to LPA ( Figure S6G ), and the tyrosine kinase inhibitors dasatinib, erlotinib, and PP2 (all at 1 mM) had no effect on the signaling pathway studied (data not shown).
Disruption of the LPA-Dock180/Elmo1-RAC-p110b Axis Affects Fibroblast Chemotaxis To assess the functional importance of the Dock180/Elmo1-RAC-p110b signaling axis for fibroblast chemotaxis, we employed transwell filter assays to study migration in gradients of LPA and PDGF. p110b-RBD-DM MEFs showed significantly reduced migration in LPA but not PDGF gradients ( Figure 7A) . Similarly, wild-type MEFs transfected with siRNA pools targeting Dock180, Elmo1, or RAC1 showed defective migration in gradients of LPA but not PDGF ( Figure 7B) , pointing to the specificity of this pathway for GPCR-induced chemotaxis. In contrast, PI3K activity was required for normal migration in either gradient, because pretreatment of wild-type cells with GDC0941 strongly affected migration toward LPA and PDGF, whereas pretreatment of cells with pertussis toxin selectively blocked migration in LPA gradients ( Figure S7A) .
In agreement with a key role of RAC upstream of p110b in fibroblast migration, acute expression of constitutively active RAC (V12-RAC1) stimulated migration of wild-type but not p110b-RBD-DM MEFs in the absence of chemoattractant and in the presence of a low concentration of LPA (10 nM) in the lower chamber, whereas migration toward 1% FCS was largely unaffected ( Figure S7B ).
p110b-RBD-DM Mice Are Protected from Bleomycin-Induced Lung Fibrosis LPA has been identified as important fibroblast chemoattractant in bleomycin-induced lung fibrosis, a well-studied mouse model of human fibrotic lung disease, and was found to be elevated in patients with idiopathic lung fibrosis (Tager et al., 2008) . We therefore wondered whether the disruption of p110b activation by LPA in p110b-RBD-DM mice would be sufficient to affect experimental lung fibrosis. Following a single intratracheal application of bleomycin, a quarter of all wild-type animals died or had to be culled according to local animal welfare regulations, whereas all p110b-RBD-DM mice survived ( Figure 7C) . Also, wild-type but not p110b-RBD-DM mice significantly lost body weight ( Figure 7D ) upon bleomycin treatment. Lung weights increased in both groups, but to a significantly lesser extent in p110b-RBD-DM mice ( Figure S7C ). Histology of lungs 14 days after bleomycin challenge revealed extended areas of fibrotic changes in wild-type animals ( Figure 7E , hematoxylin and eosin staining [H&E], top), characterized by accumulation of activated, smooth muscle antigen-positive fibroblasts (Figure 7E , middle) and deposition of crosslinked collagen fibers ( Figure 7E , Sirius red, bottom). Changes in p110b-RBD-DM mice were milder, with some mice showing almost normal lungs and others showing more limited areas of fibrosis. Morphometric analysis of multiple nonoverlapping lung areas confirmed the differences between the genotypes: transparent lung areas were significantly reduced (Figures 7F and S7D) and SMA-positive areas significantly increased ( Figure 7G and S7E) in wild-type but not p110b-RBD-DM mice when compared to saline controls.
DISCUSSION
RAS Proteins Do Not Regulate the Ubiquitous p110b Isoform
In this study, we show that, in contrast to what has been widely presumed, RAS is not a general regulator of type I PI3Ks. We find that out of the two ubiquitously expressed PI3K isoforms, only p110a is regulated by RAS, whereas p110b is a direct RAC and CDC42 target protein, indicating that key members of the pivotal RAS and RHO families of small G proteins directly regulate type I PI3Ks, with each family controlling their own distinct ubiquitous p110 isoform.
That p110b proved unable to physically and functionally interact with RAS is unexpected given the presence of a moderately conserved PI3K-type RBD in all four type I PI3K p110 catalytic subunits (Pacold et al., 2000) . Comparison between the published structures of the four RBDs in their interactor-free states reveals little pointing to the distinct interactor specificity of p110b (R. Chaleil and P. Bates, personal communication). p110b is not only unable to interact with RAS under conditions readily revealing the transient, low-affinity interactions of RAS with other isoforms, but it also has an entirely distinct RAS superfamily GTPase interactor profile with a subfamily switch from RAS to RHO at the core of it, making any, for whatever reason, undetectable interaction with RAS unlikely. RBDs, classified on grounds of a ubiquitin fold structure with interactor specificities distinct from RAS, are not uncommon, as exemplified by the human formin FHOD1, a RAC interactor (Schulte et al., 2008) , or the N terminus of Elmo1, shown to bind RHOG and the ARF family member ARL4A (Patel et al., 2011) .
RAC and CDC42 Are Isoform-Specific RBD Interactors of p110b
Our biochemical experimentation identifies RAC1 and CDC42 as RBD interactors of p110b. An association of PI3K with RAC and CDC42 was first noticed nearly 20 years ago (Tolias et al., 1995) , but was attributed to RAC/CDC42 binding to the amino-terminal BHD on p85, which has sequence homology to RHO-GAP domains (Bokoch et al., 1996; Zheng et al., 1994) . These studies left the epistasis of information transfer between RAC/CDC42 and PI3K unclear. In retrospect, all functional data from these studies can be explained by the presence of p110b in the cell lysates and PI3K preparations used. Only the reported binding of RAC and CDC42 to recombinant p85 remains puzzling. We did not study monomeric p85, which has not been found in living cells (Geering et al., 2007) , but our biochemical data strongly argue against an involvement of p85 in the RAC/CDC42-p110b interaction, because (1) RAC1 and CDC42 do not interact with p110a/ p85 or p110d/p85, (2) RAC1 and CDC42 bind normally to p110b in the absence of the p85 BH domain, and (3) RBD point mutations abrogate RAC1 and CDC42 binding to p110b in complex with fulllength p85. A body of literature has accumulated identifying RAC or CDC42 as essential upstream activators of PI3K in various systems (Keely et al., 1997; Srinivasan et al., 2003; Weiner et al., 2002) , but straightforward analysis of the relationship between RHO family GTPases and PI3K has been difficult, mainly because RAC and CDC42 also act downstream of PI3K, activated through PIP 3 -dependent GEFs (Welch et al., 2003) . A very recent study (F) p110b-RBD-DM mice are protected against loss of transparent lung areas following bleomycin instillation. Lungs were analyzed by H&E 14 days after bleomycin challenge. Multiple nonoverlapping areas of representative sections from each lung were photographed and transparent (white) areas were quantified using Nikon NIS elements software (mean ±SEM; one-way ANOVA; see Figure S7C for raw data).
(G) p110b-RBD-DM mice accumulate fewer activated lung fibroblasts following bleomycin instillation. Lungs were analyzed by immunohistochemistry for smooth muscle antigen (a-SMA) 14 days after bleomycin challenge. Multiple nonoverlapping areas of representative sections from each lung were photographed and SMApositive (brown) areas were quantified using Nikon NIS elements software (mean ±SEM; one-way ANOVA; see Figure S7D for raw data). See also Figure S7 .
using microscopy-based assays in transfected cells revisited the interaction of small GTPases and PI3K, confirming that both active RAS and RHO family GTPases can activate PI3K in living cells. However, based on experimentation exclusively with a p110a reporter construct, the authors interpreted PI3K regulation by RHO family members as indirect (Yang et al., 2012) .
RAC/CDC42 Binding to p110b Controls PI3K Activity In Vivo Our findings in MEFs suggest that RAC1 and CDC42 cooperatively control steady-state PI3K activity in living cells by isoform-specific activation of p110b and that this requires the p110b RBD. A model in which p110b provides basal, low-level PI3K activity has been proposed in the context of insulin signaling (Knight et al., 2006) , and data showing PTEN-lossdriven prostate cancers to be entirely dependent on p110b, as well as metabolic findings in p110b kinase-dead mice, have been interpreted in the same way (Ciraolo et al., 2008; Jia et al., 2008) . Our data point to RAC1 and CDC42 as drivers of such a basal, p110b-controlled activity, an idea consistent with a previous report finding that ectopic expression of wild-type but not RBD mutant p110b is sufficient to transform chicken embryo fibroblasts (Kang et al., 2006) . It will be interesting to explore the oncogenic potential of the RAC/CDC42-p110b interaction in the setting of PTEN loss and also in the context of the recently discovered activating mutations in RAC (Hodis et al., 2012; Krauthammer et al., 2012) in human melanomas, where p110b could be an important downstream target.
GPCRs Activate p110b through its RBD A firm body of in vivo evidence (Ciraolo et al., 2008; Guillermet-Guibert et al., 2008; Jia et al., 2008) has established p110b as a GPCR-regulated PI3K isoform. We find that mutation of the p110b RBD strongly attenuates p110b activation downstream of GPCRs, highlighting the importance of the RBD for p110b key signaling functions. The residual p110b activity in p110b-RBD-DM MEFs argues for a second, RBD-independent activation route, for which direct binding of Gbg to p110b (Dbouk et al., 2012) is the most obvious candidate. A puzzling question is whether a cooperative effect of RBD interactor and Gbg binding to p110b can suffice to fully activate p110b, or if additional phosphotyrosine input is required to overcome the strong inhibition of lipid kinase activity imposed by p85 (Zhang et al., 2011) . Transactivation of receptor tyrosine kinases has been suggested to activate p110b downstream of GPCRs (Yart et al., 2002) . Although we found no effect of tyrosine kinase inhibitors and no p85 tyrosine phosphorylation in response to LPA in support of such a mechanism in MEFs, there is evidence for cooperative GPCR and phosphotyrosine signaling to p110b in leukocytes (Kulkarni et al., 2011) , and such a scenario appears possible in thrombocytes, where p110b is activated by integrins, ITAMbearing receptors, and GPCRs (Martin et al., 2010) .
Dock180/Elmo1 Couples GPCRs to RAC and p110b RAC1 is essential for p110b activation downstream of the GPCRs for LPA and S1P, and the RAC-GEF Dock180/Elmo1 is upstream of both RAC and p110b in this pathway. The Dock/ Elmo-RAC signaling axis is a highly conserved pathway control-ling RAC-dependent key functions such as actin remodeling, migration, and phagocytosis (Cô té et al., 2005) . Recent findings in Dictyostelium have directly linked Gbg subunits from GPCRs to Dock/Elmo-RAC and the cytoskeleton (Yan et al., 2012) . Reminiscent of Dictyostelium ElmoE, we find the N terminus of human Elmo1 to directly bind Gbg subunits, suggesting conservation of this pathway in mammals. In line with this, PI3K activity is not required for RAC activation by LPA, placing p110b entirely downstream of RAC in fibroblasts, which contrasts with a proposed PIP 3 -driven feedback loop controlling RAC activity upstream and downstream of PI3K in leukocytes (Weiner et al., 2002) . Although PI3K is not required to activate RAC, it is still essential for fibroblast migration in gradients of LPA, indicating that PIP 3 -regulated pathways distinct from RAC activation contribute to GPCR-driven chemotaxis. Importantly, whereas our findings identify Dock180/Elmo1 downstream of LPA/S1P in MEFs, our experiments cannot rule out involvement of other RAC-GEFs within this pathway. We also cannot directly prove that the role of Dock180/Elmo1 in controlling fibroblast migration is exclusively and directly through activation of RAC upstream of p110b. Finally, different GPCRs and other cell types may signal through RAC-GEFs other than Dock180/Elmo1, and further studies will be required to determine whether the Dock180/ Elmo1-RAC1-p110b axis is a fixed signaling module or just one example of how RAC/CDC42 is activated upstream of p110b.
Overall, the picture that emerges from these studies is one in which p110b regulation by GPCRs operates through a two-track signaling pathway with direct and indirect input into p110b. The direct route involves Gbg interaction with p110b, whereas the indirect route goes through stimulation of RAC via Dock180/ Elmo1, possibly also recruited through Gbg (see Figure 6F ). Such two-track wiring is reminiscent of receptor tyrosine kinase regulation of p110a via p85 interaction with tyrosine-phosphorylated receptor or adaptor protein and Grb2-Sos-RAS-p110a interaction. It can be speculated that this signaling logic might provide an improved ability to amplify a weak signal input or might increase the possibility for fine-tuning the signal through crosstalk of other pathways onto components such as Dock180/Elmo1, RAC itself, or RAC-GAPs terminating RAC activity. Another interesting issue is whether such Gbg-Elmo1 and Gbg-p110b interactions are mutually exclusive or can occur in a heterotrimeric complex. At present, we cannot distinguish between a model in which one Gbg protein heterodimer binds directly to both Elmo1 and p110b simultaneously and one in which Elmo and p110b are engaged by two different Gbg protein heterodimers (as shown in Figure 6F ). See Supplemental Information online for the Extended Discussion, including information on other GTPase interactors of p110b, the phenotype of p110b-RBD mutant mice, and resistance of these mice to bleomycin-induced lung fibrosis.
EXPERIMENTAL PROCEDURES
Detailed procedures are described in the Extended Experimental Procedures.
Isothermal Titration Calorimetry
Purified recombinant soluble PI3K protein complexes were loaded into the cell of a MicroCal iTC200 microcalorimeter at concentrations of approximately 20 mM. Nucleotide-loaded GTPases were loaded into the syringe at 200 mM.
In a typical experiment, 16 injections of GTPase into the cell were recorded at 15 C, and relevant thermodynamic parameters were analyzed and calculated using the instrument's software (Origin).
Bleomycin-Induced Lung Fibrosis
All animal experimentation was carried out in compliance with UK Home Office animal welfare regulations. Age-and sex-matched wild-type and homozygous p110b-RBD-DM mice from intercrosses of heterozygous p110b-RBD-DM animals were used to study bleomycin-induced lung fibrosis. Mice (8-12 weeks old) were anaesthetized with isoflurane, and bleomycin in sterile normal saline (1.25 U/kg) or saline alone (50 ml) was given by intratracheal instillation. After 14 days, mice were culled and lungs were recovered for further analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Discussion, Extended Experimental Procedures, seven figures, and one table and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2013.04.031.
